PharmaLex broadens biopharma expertise

PharmaLex broadens biopharma expertise
The addition of ERA Consulting allows PharmaLex to further expand its geographic footprint as well as strengthens its biopharma capabilities

Frankfurt, Germany – February 24, 2021: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has completed the acquisition of ERA Consulting (ERA).

Founded in 1987, ERA is an international consulting firm which provides strategic product development and regulatory support and specializes in  the development of vaccines, ATMPs and cell and gene therapies. They have offices in Germany, the UK and Australia, and have an established multidisciplinary team of 20+ experts and key opinion leaders in the fields of molecular and cell biology, protein biochemistry, immunology, ATMPs, cell and gene therapy, non-clinical toxicology, manufacture, quality control, validation, and electronic submissions.

In addition to enhancing capabilities and expertise in the biopharma sector, the acquisition also expands our global geographical footprint and market reach, with a new location in Australia. Australia is considered one of the strategic hubs for early clinical trials for biotechnology companies and is therefore a perfect location for a future expansion to Asia Pacific region.

“The ERA team is excited about being part of the PharmaLex Group, as this enables us to provide additional support to our clients through the breadth of PharmaLex’s services”, explained Andrew Moore, Chief Operating Officer, ERA.

“The addition of ERA to the PharmaLex Group represents a key milestone in the company’s strategic orientation as solution provider for the biotech sector. ERA’s extensive expertise will add significant value to further build our biopharma solutions.”, explained Dr. Thomas Dobmeyer, CEO PharmaLex. “Expanding our global network into Australia is also an important step and will help us strengthen our Asia-Pacific reach”, he concluded.